A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
Open Access
- 12 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-5
- https://doi.org/10.1186/s12885-020-6624-y
Abstract
Median survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide chemo-radiotherapy. The immune checkpoint inhibitor ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and has shown clinical efficacy in preclinical models of glioblastoma. The aim of this study is to explore the addition of ipilimumab to standard therapy in patients with glioblastoma. Ipi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. Planned accrual is 120 patients (Arm A: 80, Arm B: 40). Endpoints include overall survival, 18-month survival, 5-year survival, and adverse events. The trial is currently recruiting in seven centres in the United Kingdom. ISRCTN84434175. Registered 12 November 2018.Keywords
Funding Information
- The National Brain Appeal (NBA/IpiGlio)
- Bristol-Myers Squibb
This publication has 44 references indexed in Scilit:
- Regulatory T Cells Move in When Gliomas Say “I DO”Clinical Cancer Research, 2012
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOMENeurosurgery, 2008
- Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell FunctionClinical Cancer Research, 2007
- Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant GliomaCancer Research, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR EngagementImmunity, 1996
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.The Journal of Experimental Medicine, 1995
- A new member of the immunoglobulin superfamily—CTLA-4Nature, 1987